Keane's Corner VL

CARMENA in mRCC and Surgical Management Cases in Bladder Cancer from ASCO 2018 - Tom Keane

Details
(Length of Discussion: 30 min) Tom Keane, MBBCh, FRCSI, FACS provides a detailed overview of the CARMENA study, presented by Arnaud Mejean MD, Ph.D. at ASCO 2018. This Phase III randomized trial assessed the utility and timing of CNx in the treatment paradigm of mRCC comparing patients who were randomized to either CNx and sunitinib vs sunitinib alone without CNx. He discusses the clinical applica...

Prostate Cancer Highlights from AUA 2018 with Tom Keane

Details
(Lenght of Discussion: 14 min) Tom Keane reviews three key presentations from the most recent American Urological Association (AUA) 2018 meeting. Among the presentations Keane discusses is a prostate cancer Imaging presentation by the Chief of MRI and Nuclear Medicine at the San Francisco VA Medical Center, Thomas Hope, MD. During his presentation, Prostate Cancer: What PET to GET? Hope discussed...

The Changing Landscape in Advanced Bladder Cancer - Tom Keane

Details
(Length of Discussion: 16 min) Dr. Tom Keane discusses the rapidly changing landscape in advanced bladder cancer with the introduction of immune checkpoint inhibitors. To begin his discussion he references a presentation by Thomas Powles, MD from the 2018 ASCO GU meeting where Dr. Powles provided an overview of immune checkpoint inhibitors in urothelial carcinoma at the current time and Dr. Powles...

New Concepts in ADT- Thomas Keane

Details
(Length of Discussion: 21 min) Tom Keane brings new concepts in androgen deprivation therapy (ADT) to light specifically discussing agonists versus antagonists, new androgen receptor-targeted drugs, including immunotherapy biomarkers, and genomic testing. He reviews the current state of the CRPC treatment and ADT options for use in advanced metastatic disease and concludes with a discussion on tre...

Discussion of an Online Tool to Explore Evolving Practice Patterns in Renal Cell Carcinoma - Thomas Keane

Details
(Length of Discussion: 5 min) Dr. Thomas Keane discusses a group analysis of an online tool to explore evolving practice patterns among patients with renal cell carcinoma (RCC), a topic presented by Dr. Won Kim from UCSF. The complex and rapidly evolving treatment landscape for advanced RCC poses challenges for healthcare providers, particularly those in community settings, to make treatment decis...

Discussion of the IMmotion 151 Trial: Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma - Thomas Keane

Details
(Length of Discussion: 5 min) Dr. Thomas Keane reviews the IMmotion 151 Trial, a randomized Phase III Study of Atezolizumab Plus Bevacizumab versus Sunitinib in Untreated Metastatic Renal Cell Carcinoma. A topic presented by Robert J. Motzer, MD at the 2018 ASCO GU 2018 meeting. In this oral abstract session, Dr. Motzer presented the first phase III randomized clinical trial combining a PD-L1/PD-1...

Discussion of the CABOSUN trial - Advanced Renal Cell Carcinoma - Thomas Keane

Details
(Length of Discussion: 4 min) Dr. Thomas Keane reviews the Subgroup Analysis of Progression-free Survival and Objective Response Rate in the Alliance AO31203 CABOSUN trial for Advanced Renal Carcinoma presentation by Dr. Daniel George at the ASCO GU 2018 meeting. Cabozantinib, a small molecule designed to target the MET and ALK pathways in addition to VEGFR2 pathway has been shown to be superior t...

Discussion on FALCON: Impact of 18F-fluciclovine PET/CT on Clinical Management Choices for Men with Biochemically Recurrent Prostate Cancer

Details
(Length of Discussion: 4 min) Dr. Thomas Keane provides a commentary on the The FALCON Trial , the impact of 18F-fluciclovine PET/CT on clinical management choices for men with biochemically recurrent prostate cancer presented at the recent 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium . Eugene Jueren Teoh, MBBS, MRCP from the University of Oxford presented t...

Discussion on SPARTAN: A Study of Apalutamide in Men with Non-Metastatic Castration-resistant Prostate Cancer - Thomas Keane

Details
(Length of Discussion 17 min) Dr. Thomas Keane reviews recent groundbreaking data presented at the 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium focusing on the much awaiting results of the SPARTAN trial. Dr. Keane started by highlighting the SPARTAN Trial presentation by Dr. Eric Small. A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-r...

News Update: Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer - Thomas Keane

Details
(Length of Update: 4 min) As we start a new year, Dr. Thomas Keane provides an update on exciting news in the area of non-metastatic castration-resistant prostate cancer with the FDA granting priority review for apalutamide as a treatment for non-metastatic castration-resistant prostate cancer. Currently, there are no FDA-approved treatments for patients with non-metastatic CRPC. Watch Video from...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe